The American Conference Institute’s FDA Boot Camp returns for its 42nd iteration continuing to provide the working knowledge of the core essentials of FDA law and regulation, including the new amendments under the Food and Drug Omnibus Reform Act (FDORA). A distinguished faculty of top FDA regulatory authorities—a “Who’s Who of the FDA Bar”—will share their knowledge and provide critical insights throughout the event’s workshops.
On Thursday, March 14, WilmerHale Partner Christopher Noyes will lead the “Hatch-Waxman and BPCIA in the Trenches: Exclusivity and Bioequivalency Working Group” workshop, building upon the content covered during the main conference on the regulatory and IP interplay in the Hatch-Waxman and Biologics Price Competition and Innovation Act schematics.
